Alterity Therapeutics has appointed internationally recognised expert in neurodegenerative diseases Daniel O Claassen as chief medical advisor. ... Read More The post Alterity bolsters clinical ...

Professor Günter Höglinger, Lead Investigator of the Mascot trial, said: “Completing randomization of a global Phase 3 trial in MSA is a significant achievement for the field.” He added: “Advancing ...

Theravance Biopharma (TBPH) stock is in focus as the firm halts the clinical program for rare disease therapy ampreloxetine following a trial setback. Read more here.

The company is working with Lazard on a potential sale after its lead drug candidate disappointed in a late-stage study ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Ireland-incorporated Theravance Biopharma has announced top-line results from the Phase III CYPRESS study of ampreloxetine in ...

The S&P/ASX 200 has taken an absolute beating, down almost 3% today as oil prices spike to fall sharply below ... Read More ...

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported ...

The ASX has copped a brutal $120bn wipeout as oil surges above US$100 on the Iran crisis. ... Read More The post Lunch Wrap: ASX belted more than 4pc as oil rockets past US$100 appeared first on ...

Theravance Biopharma is set to lay off 50% of its workforce, end all R&D work and scrap a blood pressure disorder drug that failed a crucial phase 3 test.  | Theravance Biopharma will lay off 50% of ...